Pharmaceutical Technology

MAY 19, 2023

Roche’s anti-CD20 monoclonal antibody Rituxan/MabThera (rituximab) is one of the most successful oncology drugs of all time. However, there is also competition with subcutaneous branded rituximab, which cannibalises Rituxan and complicates this assumption. Rituxan’s success made it a prime target for biosimilar developers.

Sales 147

Sales Production Marketing FDA Approval 147

Pharmaceutical Technology

NOVEMBER 9, 2022

Known by the brand name Roctavian, BioMarin’s haemophilia A therapy valoctocogene roxaparvovec could be fairly priced in the range of $1.95–1.96 On November 2, the Institute for Clinical and Economic Review (ICER) released its updated evidence aimed at measuring the clinical effectiveness and cost of the two haemophilia gene therapies.

Gene Therapy 278

Gene Therapy Gene FDA Approval Medicine 278

XTalks

JANUARY 20, 2025

This strategic move transformed Actavis into one of the largest pharma companies globally, with a strong presence across branded, generic and over-the-counter (OTC) medicines. Following the merger, Actavis rebranded itself as Allergan, leveraging the strong recognition of Allergans brand.

Marketing 104

Marketing Botox Life Science Pharma Companies 104

pharmaphorum

OCTOBER 6, 2022

Fresh with a new brand identity, the France-headquartered pharma group has pledged to grow its oncology sales from its current objective of €1 billion in 2025 to €3 billion in 2030, continuing a diversification of its business from its traditional focus on cardiovascular diseases. billion and $1.8

Sales 98

Sales Drugs Branding Antibody 98

The Pharma Data

MAY 27, 2022

Roche today announced that new pivotal data on its investigational CD20xCD3 T-cell engaging bispecific antibody, glofitamab, will be presented for the first time at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from 3-7 June and the European Hematology Association (EHA) 2022 Congress from 9-12 June.

Antibody 52

Antibody In-Vitro Medicine Engineer 52

pharmaphorum

MARCH 15, 2022

Sarclisa is a CD38-directed antibody that is currently approved as an intravenous therapy for relapsed multiple myeloma in combination with either Bristol-Myers Squibb’s Pomalyst (pomalidomide) plus dexamethasone or Amgen’s Kyprolis (carfilzomib) plus dexamethasone.

Trials 97

Trials Sales Drug Delivery Antibody 97

pharmaphorum

SEPTEMBER 17, 2020

There are two antibodies already on the market that target PCSK9 – Amgen’s Repatha (evolocumab) and Sanofi/Regeneron’s Repatha (alirocumab) – but these require subcutaneous injection every two to four weeks. Novartis paid a hefty $9.7 The post AZ buys oral PCSK9 cholesterol drug from Dogma Therapeutics appeared first on.

Drugs 66

Drugs Antibody Sales Branding 66

pharmaphorum

AUGUST 17, 2020

The FDA has approved Roche’s satralizumab for the rare autoimmune disorder Neuromyelitis Optica Spectrum Disorder (NMOSD), under the brand name Enspryng. The big Swiss pharma had been hoping for approva l in patients regardless of whether they have anti-aquaporin-4 (AQP4) antibodies.

FDA Approval 66

FDA Approval Antibody Branding Trials 66

XTalks

OCTOBER 22, 2021

Boehringer Ingelheim’s Cyltezo has become the second interchangeable biosimilar approved by the FDA, and the first approved interchangeable monoclonal antibody. The shorter approval time for generics along with the shorter time for development make the cost to consumers significantly lower than branded drugs.

FDA Approval 98

FDA Approval Production Insulin Antibody 98

pharmaphorum

APRIL 20, 2021

The cost-effectiveness agency has said that anti-CD20 antibody Kesimpta (ofatumumab) can be prescribed via the NHS in England and Wales as a treatment for adults with RMS with active disease, as either a first-line therapy or after alternative drugs have been tried. It was backed by NICE for NHS use in July 2018.

Sales 111

Sales Medicine Drugs Marketing 111

XTalks

JANUARY 9, 2024

In the US, some of the brand names that levothyroxine is sold under include Synthroid (from AbbVie), Levoxyl (Pfizer) and Tirosint (by Swiss manufacturer IBSA Institut Biochimique). Blocking BAFF interaction : Belimumab, which is an anti-BAFF monoclonal antibody in a Phase II trial. The thyroid disease market is huge, and lucrative.

Hormones 105

Hormones Antibody Trials Production 105

pharmaphorum

OCTOBER 22, 2020

” Roche has been studying its already-approved anti-inflammatory drug Actemra (tocilizumab), branded as RoActemra in some countries, to see if it can cut the chances of COVID patients needing a ventilator.

Development 66

Development Branding RNA Manufacturing 66

pharmaphorum

MARCH 31, 2021

Meanwhile, Novartis has secured European approval for a subcutaneous formulation of the anti-CD20 antibody ofatumumab for relapsing forms of multiple sclerosis (RMS) under the Kesimpta brand name. . “We believe this technology has the potential to transform many patients’ lives,” she added. Kesimpta approval in Europe.

Licensing 98

Licensing Licensing Gene Therapy Sales 98

XTalks

OCTOBER 27, 2021

Ranibizumab is an anti-angiogenic monoclonal antibody fragment that targets vascular endothelial growth factor A (VEGF A). Ranibizumab was developed by Genentech and is sold under the brand name Lucentis. It received FDA approval in 2018. The ocular implant is the size of a grain of rice that is placed in the upper lid of the eye.

Drug Delivery Systems 104

Drug Delivery Systems Drug Delivery FDA Approval Drugs 104

The Pharma Data

JANUARY 20, 2021

Dr Joerg Windisch, CEO of Polpharma Biologics, said “Our new brand represents our passion and dedication to innovation, we utilize the latest technology and cutting-edge techniques to discover and advance ground breaking biologics to the clinic, whether this is our own pipeline or that of our partners. This press release features multimedia.

Branding 52

Branding Manufacturing Production Containment 52

pharmaphorum

DECEMBER 29, 2021

Sanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis, now that the FDA has approved Leo Pharma’s rival antibody tralokinumab. It continues to grow strongly with Sanofi reporting a 53% rise in sales to more than $4.1

Sales 111

Sales Dermatology Marketing Allergies 111

pharmaphorum

SEPTEMBER 20, 2022

The phase 1/3 ROSALIA study showed that the copycat denosumab matched Amgen’s brand on multiple pharmacokinetics, pharmacodynamics, efficacy, safety, and immunogenicity measures in postmenopausal women with osteoporosis, said Sandoz in a statement. billion TNF inhibitor Enbrel (etanercept) and $2.25

Branding 52

Branding Medicine Marketing Sales 52

pharmaphorum

SEPTEMBER 23, 2022

Meanwhile, monthly antibody-based PCSK9 drugs – Amgen’s Repatha (evolocumab) and Sanofi/Regeneron’s Praluent (alirocumab) – reduced LDL-C by around 60%. At the time, it said AZD8233 could become a self-administered, once-monthly treatment for people with high cholesterol “with a potential best-in-class efficacy profile.”

Drugs 59

Drugs Licensing Licensing Sales 59

pharmaphorum

MAY 3, 2022

Earlier reports have suggested information was passed on programmes including an anti-HER3 antibody and drugs targeting tumour necrosis factor, BCMA and fibroblast growth factor receptor treatments. She was sentenced to eight months in prison in May 2021. Yan Mei is a fugitive who is thought to reside in China.

Scientist 69

Scientist Branding Production Antibody 69

Velocity Clinical Research

AUGUST 8, 2024

It’s been just over a year since the monoclonal antibody Lecanemab received traditional approval from the FDA as a treatment for Alzheimer’s disease. Donanemab was approved under the brand name Kisunla. So we’re learning about all the different things that have to happen to make someone have Alzheimer’s.

Clinical Trials 105

Clinical Trials Clinical Trials Genetics Clinical Research 105

XTalks

FEBRUARY 20, 2024

IgA nephropathy is an autoimmune condition characterized by the deposition of clusters of antibodies in the kidneys, resulting in inflammation and kidney impairment. These clusters, primarily comprised of IgA and other antibodies, harm the glomeruli, which are small blood vessels responsible for filtering blood in the kidneys.

Clinical Trials 59

Clinical Trials Clinical Trials FDA Approval Trials 59

pharmaphorum

APRIL 26, 2021

The drug is a nanobody, a molecule around one-tenth the size of a regular antibody derived from camelid species such as the llama. Proponents say they can offer greater stability, smaller size, higher potency, and lower production or synthesis costs compared to conventional monoclonal antibodies. billion in sales last year.

Antibody 52

Antibody Drugs Marketing Licensing 52

pharmaphorum

DECEMBER 21, 2020

The European Commission has already approved the drug under the brand name Leqvio earlier this month following backing from the CHMP regulatory committee. The FDA has not yet conducted a facility inspection and the FDA will set out a schedule if it deems one necessary, once safe travel may resume.

Drugs 52

Drugs RNA Manufacturing Licensing 52

pharmaphorum

JUNE 20, 2022

J&J has phase 2 results in hand with Tremfya in Crohn’s, but Lilly’s mirikizumab is closest behind Skyrizi, with results of a head-to-head trial pitting the antibody against Stelara due later this year.

Sales 64

Sales Trials Drugs Branding 64

pharmaphorum

OCTOBER 26, 2022

Regeneron’s activin A-targeting antibody garetosmab is due to start a phase 3 trial imminently, after showing preliminary efficacy in a phase 2 trial reported in 2020, but has also been delayed by an FDA clinical hold after fatalities were seen in the study.

Drugs 59

Drugs Genetics Marketing Trials 59

XTalks

JANUARY 27, 2023

In terms of airtime, Skyrizi, Rinvoq and Dupixent were in the top spots for the most-seen pharma brands of the year. Tremfya Maker: Johnson & Johnson Drug info: Monoclonal antibody against IL-23 for plaque psoriasis Total national TV ad spend (est.): $115.1 million — up from $70.1 million in 2021 Ranking: Up from No. million) 9.

Drugs 104

Drugs Life Science Marketing Sales 104

pharmaphorum

JANUARY 28, 2022

The marketed biosimilars are versions of big-selling brands, including Amgen’s Enbrel (etanercept), AbbVie’s Humira (adalimumab), Johnson & Johnson’s Remicade (infliximab) – all TNF inhibitors for rheumatoid arthritis and other immunological diseases.

Sales 52

Sales Marketing Branding Production 52

pharmaphorum

APRIL 6, 2022

Novartis will be hoping for a better regulatory outcome for its China-sourced PD-1 antibody than Eli Lilly, whose Innovent-licensed Tyvyt (sintilimab) was rejected by an FDA panel as a first-line treatment for NSCLC on the grounds that its application was based only on Chinese data.

Drugs 52

Drugs Licensing Licensing FDA Approval 52

pharmaphorum

JANUARY 24, 2022

Health Canada has given the drug a green light – under the Sohonos brand – to treat fibrodysplasia ossificans progressiva (FOP), making it the first treatment for the ultra-rare genetic disorder. billion takeover of Clementia Pharma in 2019. It is also the first approval for Sohonos anywhere in the world.

Drugs 52

Drugs Genetics Marketing Trials 52

pharmaphorum

APRIL 28, 2022

But the company was inspired to re-brand its rare disease business unit as a response to internal ramp-ups that have occurred over the last few years, Helfgott said. Plus, many of these small players are very good at research, not necessarily at developing or commercialising their brands,” he said.

Pharma Companies 59

Pharma Companies Branding Development Marketing 59

XTalks

FEBRUARY 3, 2022

The company is investing $1 billion of the budget into a brand-new manufacturing facility in Concord, North Carolina in the US. The anti-amyloid antibody will go head-to-head against Biogen’s Aduhelm (aducanumab), which continues to face controversy over its approval given questions about its lacklustre clinical benefit.

Manufacturing 52

Manufacturing RNA Life Science Antibody 52

The Pharma Data

SEPTEMBER 30, 2021

In mice, an antibody directed against this factor was ready to slow the expansion of metastatic tumors.Blood vessels produce protein that promotes metastases Malignant tumors spread throughout the body by releasing cancer cells into the bloodstream, which may reach distant organs and metastasize there. .”

Protein 52

Protein Scientist Antibody Research 52

The Pharma Data

JANUARY 22, 2021

When multiple mutations occur at the receptor-binding domain of the spike protein, it renders antibodies ineffective. Patrick Soon-Shiong MD, chairman and CEO of ImmunityBio, said: “There is an urgent need for a vaccine that not only offers immediate protection but also activates T cells to clear the virus.

Vaccination 52

Vaccination Vaccine Protein Immune Response 52

pharmaphorum

OCTOBER 10, 2022

Bristol-Myers Squibb claimed the first approval for a LAG-3 drug in March – getting a green light from the FDA for its relatlimab antibody in combination with its PD-1 drug nivolumab under the Opdualag brand name. Also in its favour is that LAG-3 is now a tried and tested target.

Drugs 59

Drugs Sales Marketing Trials 59

XTalks

MAY 31, 2023

Another noteworthy candidate from Acelyrin’s pipeline is lonigutamab, an anti-IGF-1R monoclonal antibody administered via subcutaneous delivery. Importantly, izokibep has demonstrated good tolerability, supporting its potential for long-term therapy.

Clinical Trials 97

Clinical Trials Clinical Trials Trials Production 97

pharmaphorum

FEBRUARY 5, 2021

The two partners have since started a clinical trial with the first drug from that collaboration – a cancer therapy – and last year 23andMe also licensed a bispecific antibody that blocks IL-36 to Spain’s Almirall.

Genetics 52

Genetics DNA Life Science Clinical Trials 52

pharmaphorum

MARCH 21, 2022

The US regulator cleared BMS’ LAG-3 drug relatlimab as a fixed-dose combination with its PD-1 inhibitor Opdivo (nivolumab) – under the Opdualag brand name – in patients aged 12 or over with unresectable or metastatic melanoma.

FDA Approval 52

FDA Approval Regulation Drugs Trials 52